HF
NRSN icon

HRT Financial’s NeuroSense Therapeutics NRSN Stock Holding History

HRT Financial’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,694
Closed -$41K – 3420
2025
Q2 		$41K Buy
+21,694
New +$31.4K ﹤0.01% 2331
2025
Q1 		– Sell
-64,390
Closed -$77K – 3116
2024
Q4 		$77K Buy
+64,390
New +$74K ﹤0.01% 2067
2024
Q1 		– Sell
-13,998
Closed -$10K – 2836
2023
Q4 		$10K Buy
+13,998
New +$9.3K ﹤0.01% 2084

Other funds holding NRSN

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

HRT Financial's NRSN Position: Q3 2025 in Review

HRT Financial sold out of NeuroSense Therapeutics (NRSN) in Q3 2025, closing a stake of 21,694 shares — an estimated $41K sold.

HRT Financial first reported a position in NRSN in Q4 2023 and held it in 3 quarters. The position peaked at $77K in Q4 2024. 10 funds tracked by Wall St. Rank hold NRSN as of Q3 2025.

  • HRT Financial reported no remaining NeuroSense Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 21,694 NeuroSense Therapeutics shares in Q3 2025, an estimated $41K.
  • HRT Financial first reported a position in NeuroSense Therapeutics in Q4 2023 and held it in 3 quarters.
  • HRT Financial's NeuroSense Therapeutics position peaked at $77K in Q4 2024.
  • 10 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.